News

MedPage Today on MSN19h
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...
New Atlas11h
Dual-target weight-loss drug is 47% more effective than its rival
The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...
Healthline11d
All About Zepbound
The maximum dosage of Zepbound is 15 mg injected once per week. The recommended maintenance dosage for adults with obstructive sleep apnea is 10 mg or 15 mg injected once per week. Your ...
Applied Clinical Trials Online1d
Tirzepatide Demonstrates Superior Weight Loss to Semaglutide in 72-Week Phase IIIb SURMOUNT-5 Trial
In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...
Mounjaro helps users lose more weight than Wegovy, new trial reveals
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...